Abstract 519P
Background
The phase Ⅲ CASPIAN study established durvalumab (D) plus etoposide with cisplatin or carboplatin (EP) as first-line standard of care (1L SoC) of ES-SCLC. The multicenter, single-arm, phase Ⅲb ORIENTAL study evaluated 1L D+EP in a large, real-world-like patient (pt) cohort in China. Preliminary safety and efficacy results were consistent with CASPIAN. Here we report final results and subgroup analysis.
Methods
Treatment-naïve ES-SCLC pts ≥18 years old with ECOG PS 0–2 received D 1500 mg + EP intravenously every 3 weeks for 4–6 cycles, followed by D monotherapy every 4 weeks until progressive disease or intolerable toxicity. Primary endpoints were immune-mediated adverse events (imAEs) and grade ≥3 AEs. Secondary endpoints included OS, PFS, and tumor response.
Results
166 pts from 32 sites were enrolled by Aug 2021 and 165 received study treatment (median [m] age 65 years; 140 [84.8%] male). At baseline, 6 (3.6%) were ECOG PS 2, 155 (93.9%) were stage Ⅳ, 21 (12.7%) had brain metastases, and 44 (26.7%) had liver metastases. By data cut-off (31 Mar 2023), median cycle number of D was 7 (range 1–25). 92 (55.8%) started subsequent systemic anticancer therapy. 40 (24.2%) reported imAEs (most common [≥5%]: hyperthyroidism [6.1%] and hypothyroidism [6.1%]; grade 1/2 mostly). Grade ≥3 AEs occurred in 82 (49.7%) pts and led to treatment interruption in 24 (14.5%). mOS was 14.8 months (mo) (m follow-up [mFU] 20.5 mo). 118 (71.5%) pts received D maintenance, with mOS of 16.6 mo. 85 (51.5%) pts received >4 EP cycles, with mOS of 17.4 mo (Table). mPFS was 6.3 mo (mFU 8.6 mo). ORR was 76.4%, with 3 (1.8%) complete responses (RECIST 1.1). Table: 519P
N=165 | 95% CI | ||
Any-cause AEs, n (%) | 161 (97.6) | ||
Grade ≥3 AEs, n (%) | 82 (49.7) | ||
imAEs, n (%) | 40 (24.2) | ||
Grade ≥3 imAEs, n (%) | 11 (6.7) | ||
mOS, mo | 14.8 | 13.2–16.0 | |
12-mo OS, % | 60.8 | 52.8–67.9 | |
24-mo OS, % | 26.2 | 17.5–35.6 | |
mPFS, mo | 6.3 | 5.6–6.5 | |
12-mo PFS, % | 17.6 | 12.0–24.1 | |
ORR, % | 76.4 | 69.1–82.6 | |
DCR, % | 89.1 | 83.3–93.4 | |
mDoR, mo | 5.1 | 4.7–5.7 | |
Subgroup analysis | n | mOS, mo | 95% CI |
Received D maintenance | 118 | 16.6 | 15.1–18.8 |
ECOG PS | |||
0–1 | 159 | 15.1 | 13.3–16.1 |
2 | 6 | 9.2 | 6.4–Not Available |
Number of EP cycles | |||
≤4 | 80 | 12.7 | 9.4–15.1 |
>4 | 85 | 17.4 | 14.0–21.7 |
First-line platinum | |||
Cisplatin | 17 | 11.1 | 6.5–18.8 |
Carboplatin | 148 | 15.2 | 13.3–16.6 |
Brain metastases | |||
With | 21 | 11.1 | 8.5–14.3 |
Without | 144 | 15.3 | 13.3–17.4 |
Liver metastases | |||
With | 44 | 9.6 | 6.5–13.2 |
Without | 121 | 16.1 | 14.3–18.2 |
Conclusions
Final results of ORIENTAL showed in the largest to date, real-world-like Chinese ES-SCLC cohort that D+EP was effective and well tolerated, further supporting D+EP as 1L SoC in China.
Clinical trial identification
NCT04449861.
Editorial acknowledgement
Medical writing support for the development of the abstract, under the input and direction of the authors, was provided by Xiaowei Ning and Bo Lyu from Costello Medical Singapore and funded by AstraZeneca China.
Legal entity responsible for the study
AstraZeneca China.
Funding
AstraZeneca China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
581P - The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer
Presenter: Wen-Chen Tang
Session: Poster Display
Resources:
Abstract
582P - Furmonertinib treatment in patients with EGFR-mutated non-small cell lung cancer and leptomeningeal metastases: A real-world study
Presenter: Haiyang Chen
Session: Poster Display
Resources:
Abstract
583P - RHBDL2 promotes non-small cell lung cancer metastasis and osimertinib resistance by activating the RAS/MEK/ERK signaling pathway through interaction with FGFR
Presenter: jun Deng
Session: Poster Display
Resources:
Abstract
584P - Upfront aumolertinib for preventing symptomatic central nervous system(CNS) metastases in EGFR-mutant non-small cell lung cancer without baseline CNS metastasis
Presenter: Tangfeng Lv
Session: Poster Display
Resources:
Abstract
585P - Real-world outcomes in patients with non-small cell lung cancer with EGFR exon 20 insertion mutations receiving mobocertinib
Presenter: Tony S.K. Mok
Session: Poster Display
Resources:
Abstract
586P - Clinical validation of a multiplex polymerase chain reaction (mPCR) assay to identify patients (pts) with NSCLC suitable for mobocertinib treatment
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
587P - Exploring the prevalence and characteristics of human epidermal growth factor receptor 2 (HER2) alterations in non-small cell lung cancer: Analysis from a Malaysian cohort
Presenter: Ning Yi Yap
Session: Poster Display
Resources:
Abstract
588P - First real-world study with HER2 ADC in treating HER2-altered non-small cell lung cancer
Presenter: Kaihua Lu
Session: Poster Display
Resources:
Abstract
590P - A retrospective study of the prevalence and clinical outcomes of KRAS G12C mutated advanced non-small cell lung cancer (NSCLC) in Australian patients (pts)
Presenter: Ben Markman
Session: Poster Display
Resources:
Abstract
591P - The utility of next generation sequencing for KRAS gene variants prevalence in cytological and tissue samples in real-world NSCLC patients: A large single institution real-world study
Presenter: Adam Pluzanski
Session: Poster Display
Resources:
Abstract